பல்கலைக்கழகம் ஆஃப் நோட்ரே டேம் டு லட்சம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பல்கலைக்கழகம் ஆஃப் நோட்ரே டேம் டு லட்சம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பல்கலைக்கழகம் ஆஃப் நோட்ரே டேம் டு லட்சம் Today - Breaking & Trending Today

Claiming damages in IP cases in Mexico


June 02 2021
A new law regulating industrial property rights in Mexico was published in the Official Gazette on July 1 2020.
In addition to notable improvements in respect to the protection of patents, trademarks and other industrial property rights, the new Federal Law for the Protection of Industrial Property has significantly altered the possibilities for claiming damages arising from the infringement of trademarks and other industrial property rights, making potential awards for such damages a far more realistic possibility.
Under the defunct Industrial Property Law, the owner of a registered trademark or other industrial property right had two options for seeking redress for infringement. ....

Eduardo Kleinberg , Universidad Anahuac , Basham Ringey Correa , Supreme Court , University Of Notre Dame Du Lac , Euromoney Institutional Investor , University Of Chicago , Official Gazette , Federal Law , Industrial Property , Industrial Property Law , Mexican Institute , Instituto Mexicano De La Propiedad Industrial , Federal Code , Civil Procedure , Basham Ringe , Ceneval Award , Academic Excellence , Notre Dame , Privacy Notice , Institutional Investor , யுனிவர்சிடாட் அன்ஹுஅக் , உச்ச நீதிமன்றம் , பல்கலைக்கழகம் ஆஃப் நோட்ரே டேம் டு லட்சம் , பல்கலைக்கழகம் ஆஃப் சிகாகோ , அதிகாரி கஸெட் ,

SPARC announces positive top-line results for ophthalmic drug


Sun Pharma Advanced Research Company (SPARC) announced positive top-line results from pivotal phase 3 clinical trial of PDP-716 for the treatment of ocular hypertension.
SPARC reported positive top-line results from its Phase 3 trial (CLR 16 33) for its investigational drug, PDP-716 ophthalmic suspension, for the treatment of open angle glaucoma or ocular hypertension.
PDP-716 is a novel, once daily, ophthalmic suspension of Brimonidine Tartrate 0.35%. PDP-716 is developed using SPARC s proprietary TearAct technology.
The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day.
We are very pleased by these results for PDP-716. Once daily dosing of PDP-716 can significantly reduce the dosing frequency compared to currently marketed formulation and can have positive impact on quality of life for patients with Glaucoma. said Anil Raghavan, CEO of SPARC. ....

Dilip Shantilal Shanghvi , Aashish Maheshwari , Rekha Jhunjhunwala , Abakkus Growth Fund , University Of Notre Dame Du Lac , Sun Pharma Advanced Research Company , Brimonidine Tartrate , Sanil Raghavan , Authum Investment , Notre Dame , Cohesion Investment , Capital Market , Bse Sensex , Nifty 50 , Sun Pharma , Pharmaceutical Companies , Kite Pharma , Biotechnology Amp Medical Research Nec , Sanil Raghavan , Brimonidine Tartrate , Sun Pharma Advanced Research Company , Rekha Jhunjhunwala , University Of , நீர்த்துப்போக சாந்திலால் ஷாங்க்வி , ஆஷிஷ் மகேஸ்வரி , ரேகா ஜுன்ஜுன்வாலா ,

SPARC to raise ₹1,201 cr from promoter, 34 others - The Hindu BusinessLine


SPARC to raise ₹1,201 cr from promoter, 34 others
May 12, 2021
The board of director of Sun Pharma Advanced Research Company Ltd on Wednesday approved a proposal to raise up to ₹1,200.97 crore to Dilip Shantilal Shanghvi, Promoter of the company and to 34 other non-promoter group persons, including Rekha Jhunjhunwala, Authum Investment, University of Notre Dame DU Lac, Cohesion Investment (Cayman), Ashish Maheshwari and Abakkus Growth Fund, by way of preferential issue.
The board has approved to issue up to 6.75 crore warrants each convertible into, or exchangeable for, one equity share within the period of 18 months at ₹178 each.
Shares of SPARC jumped 6.14 per cent at ₹239.55 on the BSE. ....

Dilip Shantilal Shanghvi , Aashish Maheshwari , Rekha Jhunjhunwala , Sun Pharma Advanced Research Company Ltd On , Abakkus Growth Fund , University Of Notre Dame Du Lac , Sun Pharma Advanced Research Company Ltd , Authum Investment , Notre Dame , Cohesion Investment , நீர்த்துப்போக சாந்திலால் ஷாங்க்வி , ஆஷிஷ் மகேஸ்வரி , ரேகா ஜுன்ஜுன்வாலா , பல்கலைக்கழகம் ஆஃப் நோட்ரே டேம் டு லட்சம் , நோட்ரே டேம் ,